How can the binding affinity of anti-Rat IgG(Fc)-N-MMAF ADC to its target be validated?

The binding affinity of anti-Rat IgG(Fc)-N-MMAF ADC to its target can be validated using techniques such as surface plasmon resonance (SPR) or enzyme-linked immunosorbent assay (ELISA). These methods can confirm the ADC's ability to bind specifically to rat IgG Fc receptors on target cells, ensuring effective delivery of the cytotoxic agent.

What are the recommended washing steps when using anti-Rat IgG(Fc)-N-MMAF ADC in cell-based assays?

When using anti-Rat IgG(Fc)-N-MMAF ADC in cell-based assays, it is recommended to include thorough washing steps to remove unbound ADC. Typically, washing the cells with PBS 2-3 times after incubation helps reduce background signals and ensures that only specifically bound ADC contributes to the observed cytotoxic effects.

How should anti-Rat IgG(Fc)-N-MMAF ADC be handled to avoid degradation during experiments?

To avoid degradation, anti-Rat IgG(Fc)-N-MMAF ADC should be handled under sterile conditions and kept on ice during experimental setup. The ADC should be protected from light and stored in small aliquots to minimize freeze-thaw cycles, which can degrade the conjugate and reduce its effectiveness.

How can off-target effects be minimized when using anti-Rat IgG(Fc)-N-MMAF ADC?

Off-target effects can be minimized by optimizing the concentration of anti-Rat IgG(Fc)-N-MMAF ADC and ensuring that it is used only with cells expressing the appropriate rat IgG Fc receptors. Additionally, using specific blocking agents or controls can help confirm the specificity of the ADC's action.

What is the significance of glycosylation in the Fc region of anti-Rat IgG(Fc)-N-MMAF ADC?

Glycosylation in the Fc region is essential for the binding of anti-Rat IgG(Fc)-N-MMAF ADC to Fc receptors on target cells. This interaction is necessary for the internalization and cytotoxic action of the ADC. Variations in glycosylation patterns can affect the ADC's efficacy, making it important to ensure consistent glycosylation during production.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-Rat IgG(Fc)-N-MMAF ADC

anti-Rat IgG(Fc)-N-MMAF ADC (CAT#: ADC-AA-039)

This ADC product is comprised of an anti-rat IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF. The antibody portion is a secondary antibody and the drug portion, MMAF, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
anti-rat IgG Fc specific polyclonal IgG antibody

Species Reactivity
Rat

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
MMAF (Monomethyl auristatin F)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-039. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

The anti-Rat IgG(Fc)-N-MMAF ADC has been a reliable tool in our rat monoclonal antibody screenings. Its low toxicity and strong efficacy have significantly improved our research outcomes.

Excellent

Creative Biolabs' anti-Rat IgG(Fc)-N-MMAF ADC offers impressive specificity and efficiency. The product's ability to induce cell death without added toxicity has streamlined our ADC candidate evaluations.

Excellent

We found the anti-Rat IgG(Fc)-N-MMAF ADC to be highly effective in our experiments. The noncleavable linker to MMAF works seamlessly, providing consistent and reliable results.

Excellent

The anti-Rat IgG(Fc)-N-MMAF ADC from Creative Biolabs is an excellent alternative for ADC candidate screening. Its efficiency and safety have exceeded our expectations in every use.

Excellent

Using the anti-Rat IgG(Fc)-N-MMAF ADC has greatly enhanced our research process. The product's cytotoxicity paired with its lack of toxicity without a primary antibody makes it invaluable.

Q: 1: How can the binding affinity of anti-Rat IgG(Fc)-N-MMAF ADC to its target be validated?
A: The binding affinity of anti-Rat IgG(Fc)-N-MMAF ADC to its target can be validated using techniques such as surface plasmon resonance (SPR) or enzyme-linked immunosorbent assay (ELISA). These methods can confirm the ADC's ability to bind specifically to rat IgG Fc receptors on target cells, ensuring effective delivery of the cytotoxic agent.
Q: 2: What are the recommended washing steps when using anti-Rat IgG(Fc)-N-MMAF ADC in cell-based assays?
A: When using anti-Rat IgG(Fc)-N-MMAF ADC in cell-based assays, it is recommended to include thorough washing steps to remove unbound ADC. Typically, washing the cells with PBS 2-3 times after incubation helps reduce background signals and ensures that only specifically bound ADC contributes to the observed cytotoxic effects.
Q: 3: How should anti-Rat IgG(Fc)-N-MMAF ADC be handled to avoid degradation during experiments?
A: To avoid degradation, anti-Rat IgG(Fc)-N-MMAF ADC should be handled under sterile conditions and kept on ice during experimental setup. The ADC should be protected from light and stored in small aliquots to minimize freeze-thaw cycles, which can degrade the conjugate and reduce its effectiveness.
Q: 4: How can off-target effects be minimized when using anti-Rat IgG(Fc)-N-MMAF ADC?
A: Off-target effects can be minimized by optimizing the concentration of anti-Rat IgG(Fc)-N-MMAF ADC and ensuring that it is used only with cells expressing the appropriate rat IgG Fc receptors. Additionally, using specific blocking agents or controls can help confirm the specificity of the ADC's action.
Q: 5: What is the significance of glycosylation in the Fc region of anti-Rat IgG(Fc)-N-MMAF ADC?
A: Glycosylation in the Fc region is essential for the binding of anti-Rat IgG(Fc)-N-MMAF ADC to Fc receptors on target cells. This interaction is necessary for the internalization and cytotoxic action of the ADC. Variations in glycosylation patterns can affect the ADC's efficacy, making it important to ensure consistent glycosylation during production.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-052	Protein A-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-048	Protein G-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-029	anti-MIgG(Fc)Fab-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-051	Protein G-Duocarmycin ADC		Duocarmycins

CAT#	Product Name	Linker	Payload
ADC-AA-018	anti-HIgG(Fab)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-037	anti-RIgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-015	anti-HIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-019	anti-MIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-034	anti-RIgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-AA-020	anti-MIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-W-537	Anti-TPBG-Mc-MMAF ADC	Mc (maleimidocaproyl)	MMAF (Monomethyl auristatin F)
ADC-AA-019	anti-MIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-001	anti-HIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.